Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Evaluation of AVJ-301 (Absorb BVS), the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Japanese Population

Trial Profile

A Clinical Evaluation of AVJ-301 (Absorb BVS), the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Japanese Population

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms ABSORB Japan
  • Sponsors Abbott Vascular
  • Most Recent Events

    • 25 Sep 2018 Results reporting influence of procedural technique on Everolimus-Eluting Stent outcomes within the ABSORB trials (ABSORB II, ABSORB III, ABSORB China and ABSORB Japan) presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 09 Nov 2016 According to an Abbott Healthcare media release, the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Absob BVS as device for patients with coronary artery disease based on results of this trial.
    • 08 Oct 2016 Results of subgroup analysis assessing the baseline optical coherence tomography (OCT) data of the Absorb BVS arm of the OCT group 1 (n=125), published in the Circulation Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top